Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Damn, man, I linked the 2015 10-K that talked about Sanofi. What do you think happened to the KBIO shares, when the company changed their name to Humanigen in 2017?
We still have our shares.
How can they be taken away if all the creditors are paid, and we're still in CH11, and not in CH7? Maybe our shares will remain intact, or maybe they will change to Taran shares, or shares in the Sanofi/Taran merger entity. I don't know, man. It just seems obvious to me that the judge would not let the liquidating trustee erase our shares.
again , i have read almost all the k/q since 2017 and never saw the name sanofi a single time .
its all made up in your head jay
right terminated before humanigen came into existence.
there is no connection with sanofi jay
so the judge is protecting all the creditors except the shareholders?
No, I can't now, without doing a helluva lot of research on my old posts. But there are posters who still have search capability here, and it would be easier for one of them to find the posts in question.
Just a Google search found this.
https://www.wsj.com/articles/DJFVW00020121005e8a5mqn3m
So evidence of a partnership, which seems to have served its purpose.
"Sanofi
In January 2010, we entered into an agreement with Sanofi pursuant to which we granted to Sanofi an exclusive worldwide license to develop and commercialize KB001 (the precursor molecule to KB001-A), KB001-A and other antibodies directed against the PcrV protein of Pa for all indications but retained rights relating to Pa in patients with CF or bronchiectasis. In July 2014, we executed an agreement with Sanofi under which the Sanofi agreement was terminated."
see pg 14
https://www.sec.gov/Archives/edgar/data/1293310/000121465916013550/s82516010k.htm
you will have closure shortly.
you need to move on with life .
durrant and dave chapell already took your money and did it nicely
It's so easy to see some important things, chiefly, the amended Asset Purchase Agreement, which established additional Milestone Events, and increased the amount of payments. The judge is telling us that he recognizes the likelihood of some type of regulatory approval, which I think we'll see from Australia as the result of our PREACH-M trial for CMML.
jay simply show the board that sanofi has ownership in humanigen
i know you cannot
I hope and pray even 1/10 of a percent of what you say comes true! Trust me I really want / need for you be right about everything here! :))
I'm not in the least bit worried here. The pieces are coming together. My only concern will be in trying to get my sell orders re-entered. They expired today.
the last report YOU SAW has sanofi w
ownership of humanigen ( kalobios shares)
can you post that report / proof you claim to possess or is it something you saw 7 years ago?
i would suggest sanofi does not own squat in humanigen.
i would suggest there is no partnership because there is no evidence …
there is no vaccine adjuvant either
but you are convinced it is true.
but you cant name a single thing you have predicted that has come through jay .
seven years going on 8
it has been nothing but scam after scam. if it wasnt hedge funds skimming money to the caymen islands, to insiders selling for big time money , to a CEO going on fox news broadcasting falsely the efficacy of this drug.
all scams jay
sorry
The, "...court recognized developments (details of which appear to be redacted), that will bring sufficient value to have justified an amendment to the Asset Purchase Agreement, allowing for additional Milestone Events and higher payments. So there will be no reason to decline a distribution to existing equity holders. It is clear that favorable regulatory approval/authorization is required to enact Milestone payments."
The court recognized the feasibility of Humanigen's ability to meet the CH11 obligations.
"G. Feasibility
Here, the Combined Plan and Disclosure Statement provides for the liquidation and
distribution of all of the Debtor’s remaining Assets. Accordingly, the Debtor believes all chapter
11 plan obligations will be satisfied without the need for further reorganization of the Debtor. "
pg 35/69
https://document.epiq11.com/document/getdocumentbycode?docId=4343521&projectCode=HUM&source=DM
The last report that I saw reflected that Sanofi was holding just under 5% of our (then Kalobios) shares. So they would have significant financial benefit in the event of a recall of our loaned shares, or merger news.
Sanofi would have significantly more financial benefit if Humanigen/Taran enacted the plan they previously suggested, details which included providing a merger partner with ~238,160,270 shares of our stock (which is twice as high as our current OS). I determined that they would accomplish this by declaring a 5:1 forward split, (temporarily?) increasing our OS to 595,400,675 shares.
In any event, I have been saying that achieving any Milestone Event would fully satisfy all creditors, and provide for a Distribution to existing equity holders. It was nice to have validation of that opinion expressed by management.
I know that I'm missing something significant about Sanofi, so I decided to consider them in terms of the merger details previously discussed. So maybe this will conclude with our joint ownership of a merger entity with Sanofi.
MWM
@MWM76
I’ve been there done that. Humanigen’s drug worked as well, but not enough statistically. Now you think in the most difficult of diseases Remi is going to crack the code on Alzheimer’s, like I’ve said before, good luck with that…
10:20 AM · Jul 2, 2024
·
22
Views
Jay Booth
@booth37337
·
9m
WHAT THIS STUDY ADDS. Participants with baseline CRP <150 mg/L represented 78% of the LIVE-AIR study population and demonstrated the greatest improvement in SWOV with lenzilumab, through day 28 (HR: 2.54; 95% CI 1.46 to 4.41; p=0.0009).
From thorax.bmj.com
https://thorax.bmj.com/content/78/6/606
I’ve been there done that. Humanigen’s drug worked as well, but not enough statistically. Now you think in the most difficult of diseases Remi is going to crack the code on Alzheimer’s, like I’ve said before, good luck with that…
— MWM (@MWM76) July 2, 2024
For your further consideration, Diego, "...based on the words used in the filings..." we have the following.
"2. Milestone Payments
The Purchaser, the Foreign Subsidiary, and any other entity that is an Affiliate of the
Purchaser or Foreign Subsidiary that acquires any of the Acquired Assets (the “Regulatory
Milestone Parties” which Regulatory Milestone Party shall include any entity that merges with or
enters into a joint venture with any of the Regulatory Milestone Parties), may be obligated to pay
to the Debtor or its successor or assignee (including, but not limited to, statutory trustees, plan
trustees, plan administrators, litigation trustees, and liquidating trustees) certain contingent
payments (the “Milestone Payments”) in consideration for the Acquired Assets upon achievement
of certain development and commercial milestone events..."
pg 29/69
https://document.epiq11.com/document/getdocumentbycode?docId=4343521&projectCode=HUM&source=DM
Now, this may not be, "...how bankruptcy proceedings typically transpire." (Just messin' with you, SG44), but Durrant and Dale are not typical executives treading in these murky waters. They were hugely successful with the recall of the loaned shares of Kalobios. No, this was not strictly Shkreli. He appointed Dale and Durrant to the KBIO Board, and Durrant was in the CEO's chair while it was still warm after Shrkreli's departure. They, alone, navigated through KBIO's bankruptcy, and kept the shareholders whole coming out of that bankruptcy, achieving the biggest short squeeze that has yet to be surpassed...that is, until Humanigen/Taran does that, as we will.
Bottom line is, I think Humanigen/Taran's lenzilumab is what enhanced Novavax's covid vaccine to the point that Sanofi wants to use the NVAX vaccine with their flu vaccine. Doubtless, Sanofi, like Gracell and Mayo Clinic, and like our PREACH-M and RATinG trial sponsors, is also eager to use lenz with their cancer treatment platform. I fully expect that Filip Dubovsky will join us, and use his extensive Product Development experience to help us to achieve what he helped Novavax to achieve.
Docket List
https://dm.epiq11.com/case/humanigen/dockets
Just making note of the Docket List in the title of the post, so I don't have to keep searching for it.
And yes, I still see a pathway toward our success.
Okey, thank you very much. And is there any date in mind?
I will add, as I had been looking for this quote from Docket 295: Declaration in Support of the Combined Chapter 11 Plan of Liquidation by Craig Jalbert a Humanigen Director.
I previously discussed the market's response to our LIVE- AIR topline data (TLD) which allowed me to sell shares for an average price in the $28 range. To now reach a Milestone Event, as the court deems is likely, based on amending the Asset Purchase Agreement, would require receipt of a BLA or regulatory approval, and that would have a greater share price reaction than the news of our TLD.
Even non-regulatory news, such as a merger leading to a business relationship with Sanofi/Novavax, would cause a spike in the share price. Given that I think Humanigen has control of about 90% of the shares they have issued, here again, more than enough profit could be generated by the company selling shares into that news, to pay off all financial obligations.
I am convinced that the positive events I just outlined will transpire. It doesn't make sense that the company would deal us out of the reward following good news. Payment in full to creditors would amount to a pittance of what would be gained in a short squeeze.
There are basically two differing schools of thought here:
1: Shareholders will receive nothing as the company has been dissolved. Many posters/shareholders here fall into this category based on the words used in the filings, and view of how bankruptcy proceedings typically transpire.
2: Shareholders will become whole with some sort of distribution thanks to the agreed on Milestone Payments included in the sale document to Taran & that we may receive shares in Taran. Jay is the most vocal believer in this outcome (though I'm sure not alone), and it is based on belief in management and experience with similar situations occurring with said management.
Which route you believe in is entirely up to you. Hope this helps explain things more simply.
Hi, could you explain what's happening with hgen in a simple way, I don't have a lot of knowledge in this area and sometimes I don't get what you guys are talking about
Technically speaking, those of us with existing equity interest fall into General Unsecured Claims which makes us a creditor. The difference here is that we have been split into Class 5 with said existing equity interest.
Throughout the Combined Plan it is stated multiple times that no distribution to Class 5 is anticipated. However, if somehow they receive more $ from liquidation than previously thought and have already paid off Class 3 creditors we would receive our share of the proceeds which would require the Liquidating Trustee to set a Record Date for that distribution. As a reminder - there is a reason we were not allowed to vote on the plan and a "no" was assumed and recorded for all Class 5 members, that is because no one would vote "yes" on a plan where they receive $0 in recovery.
Distributing payments to creditors is only part of the Liquidating Trustee's function. Making a Distribution to existing equity holders is also part of his function. I don't know how he can do that, if our float is 192% of our OS.
I see divergent paths chosen by the judge and the Liquidating Trustee. If the judge is right, which appears likely to me, then there is no need for the Liquidating Trustee.
Hopefully, we'll hear news including Sanofi, the PREACH-M and RATinG trials, and Novavax, before the Liquidating Trustee proceeds much further.
Just following the logic train - because their sole purpose is to liquidate and distribute payments to creditors accordingly. So while yes, business adjacent things like receiving milestone payments may take place, it's not for furtherance of profit...instead it's to pay creditors.
How can the Liquidating Trustee have no objective to continue or engage in the conduct of a trade or business, when the judge sees cause to have amended the Asset Purchase Agreement, and significantly expand the number of Milestone Events, and increase payments?
Further, if our Transfer Agent reports significantly more Cede shares in circulation than reported by the DTC, then that presents a Cause of Action incumbent on the Liquidating Trustee to reconcile.
Purpose of liquidating Trust found on page 39 and 42 of the Combined Plan:
Thanks again, SorcererGuru44. I should have caught the 2012 date. I wonder if we'll see another filing to modify the Combined Plan. As far as I know, that may still be intended.
The Amended Standing Order of Reference for the District of Delaware does not exactly have anything to do with our specific case, but is the legal basis granting court jurisdiction over Title 11 proceedings. Ultimately, the Standing Order is the order stating all Title 11 proceedings from this district will be managed by this district. You can view the document here:
https://www.ded.uscourts.gov/sites/ded/files/general-orders/AmendedTitle11Order_2-29-12.pdf
If you would like more information on the US code, specifically 28 USC 157 which grants each district the ability to hear cases (among other things) from that district you can follow the link here:
https://www.law.cornell.edu/uscode/text/28/157
or by viewing the civil resource manual here:
https://www.justice.gov/jm/civil-resource-manual-186-reference-proceedings-bankruptcy-judges#2;.
I wonder how the Liquidating Trustee is going to declare a distribution to existing equity holders, who hold far more shares of HGEN than the company issued. Am I going to get a distribution based on my oldest shares, but not my newest shares? For that matter, if InhibRx-styled news is released by which we establish a business relationship with Sanofi, and an advanced Purchase Agreement results in the payment due to all of our creditors, what need do we have of the Liquidating Trustee?
Docket List:
https://dm.epiq11.com/case/humanigen/dockets
To see Sanofi audit two years of financial data was likely done to satisfy terms of a partnership or merger. At least, I haven't seen any Regulatory pressure on Sanofi in that regard. Sanofi and Novavax have already announced their co-licensing and co-commercializing agreement for Sanofi to combine Novavax's covid vaccine, in combination with Sanofi's flu vaccines.
Jean-Francois Toussaint, Sanofi's Global Head of Vaccines R&D, said, "We’re excited by the prospect of combining Novavax’s adjuvanted COVID-19 vaccine that has shown high efficacy and favorable tolerability, with our rich portfolio of differentiated flu vaccines."
https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-10-06-00-00-2879379
Remember, the EMA wanted Novavax to validate their greatly-enhanced covid vaccine efficacy, which Novavax confirmed within weeks. I think the patented lenz/vaccine cocktail accounted for this improved performance.
With healthcare providers looking away from mRNA products, Novavax will own the covid market with their enhanced protein-based vaccine. If it is confirmed that the patented application of lenzilumab into the Novavax vaccine, accounted for the product's increased safety and efficacy, then lenz will share that market dominance not only of the covid market, but perhaps of Sanofi's flu vaccine market, as well.
Humanigen could meet all creditor obligations and exit the bankruptcy with just 1/10th of the Advanced Purchase dollars that Sanofi provided to Novavax, which removed the going-concern status from them. This may be why management stated they were reserving the right to further modify the Combined Plan, which I believe HAS to be modified to account for lenzilumab's market placement through licenses granted by the company to Sanofi and Novavax.
True, the Bar Date is Monday. I wish we all knew more than what has been communicated. I'm really interested in the Amended Standing Order of Reference from the United States District Court for the District of Delaware. I wonder if that is in relation to Dale's entities. And I wish we knew more about the motivation of the Liquidating Trustee.
Doc 190, pg 1
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1067958&projectCode=HUM&docketNumber=190&source=DM
But what we DO know about is the amended Asset Purchase Agreement, in anticipation of expanded Milestone Events and increased payments. I really think the bedrock of this expansion is going to come from Sanofi. I'd like to see confirmation of that, just as I would like to see news about licensing lenz to Sanofi and Novavax, for the lenz-enhanced covid vaccine.
i guess i am dumber than a fence post
july is approaching so we will have closure shortly
You know me well enough to know that, as I have often said, "To me, part of the reason for investing here has always been a stock play, such they executed previously DBA Kalobios."
https://moxreports.com/kbio-infinity-squeeze/
When management provides guidance that the Liquidating Trustee has sole discretion to declare a Distribution, but that no distribution is expected to existing equity holders, I have to acknowledge that. But I think you'd have to be dumber than a fencepost to believe that. The judge would not have approved the amended Asset Purchase Agreement, without the expectation that Humanigen was going to reach specified Milestone Events, which are triggered by some sort of Regulatory authorization or approval. Reuniting the share structure with the Intellectual Property rights is, for people like our management, a relatively simple task to merge Humanigen and Taran. I think it could be similar to what we saw from InhibRx.
"Prior to the closing of the acquisition, Inhibrx completed the spin-off of Inhibrx Biosciences, Inc. (“Inhibrx Biosciences”), distributing 92% of Inhibrx Biosciences’s shares to holders of shares of Inhibrx common stock as of May 17, 2024. Inhibrx Biosciences, which was a wholly owned subsidiary of Inhibrx prior to the distribution, acquired all of the assets of Inhibrx not related to SAR447537, which include INBRX-109 and INBRX-1061, as well as all Inhibrx employees, pursuant to an internal reorganization. Inhibrx continues to own the remaining 8% of Inhibrix Biosciences following the completion of the transactions. Inhibrx Biosciences began trading on the NASDAQ Global Market on May 30, 2024, under the ticker “INXB” and, beginning on May 31, 2024, will trade under the ticker “INBX”.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524150383/d843856dex991.htm
There is no way that I see management proceeding without the shareholders. Identifying the existing equity holders will be determined by our Transfer Agent, rather than the DTC. I expect that journal to reflect a float that is 192% of our OS, and the Distribution will force a buy-in of all the shares in our market.
The forced buy-in, news regarding lenzilumab's safety and efficacy for CMML, as well as aGvHD, lenzilumab's performance in improving CAR-T and enhancing non-mRNA covid vaccines, plus news regarding Sanofi and Novavax, regarding not only licensing deals, but additional partnership status updates, will rock our market, and hopefully allow me to make some sells Monday.
The unfolding truth of excess deaths and Serious Adverse Events from mRNA vaccines will result in demand for lenz far surpassing the $1B revenue goal initially targeted by the company. I suspect there will be a market from infected, non-hospitalized patients with elevated CPR levels. Lenz demonstrated an 8-fold improvement in treating patients with <41mg/L of CRP.
I just don't think we have ever been stronger, despite appearances, which can change in the blink of an eye.
I see that Sanofi has just filed Financial Statements and Supplemental Schedules for the years ended Dec 31, 2022 AND 2023, for both the US and Puerto Rico Group Savings Plans. I guess they're getting ready for Q3, and the spinoff of their healthcare sector.
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001121404&owner=include&count=40&hidefilings=0
Here, recently, we saw Humanigen file an Objection to equity claims filed by a relatively small number of holders
But we also saw that management planned to confirm the court's position on our conformance to the bankruptcy rules. They also reserved the right to modify the Combined Plan, if required to do so.
I think the Plan HAS to be modified, for two reasons. One reason is because the court recognized developments (details of which appear to be redacted), that will bring sufficient value to have justified an amendment to the Asset Purchase Agreement, allowing for additional Milestone Events and higher payments. So there will be no reason to decline a distribution to existing equity holders. It is clear that favorable regulatory approval/authorization is required to enact Milestone payments.
The very number of shares in Humanigen's market is, itself, a share price catalyst. whether the share structure was disclosed in the redacted information, or not. I would hope that the judge was advised of our share structure, but regardless, that information will be public knowledge as soon as we get the regulatory news of approval, such as for the treatment/prevention of CMML cancer, or whether the news comes in terms of unfolding business developments/alignments.
"Confirmation pursuant to section 1129(b) of the Bankruptcy Code requires any such modification."
Here is the cited section of the Code.
"11 U.S. Code § 1129 - Confirmation of plan
(b)
(1)Notwithstanding section 510(a) of this title, if all of the applicable requirements of subsection (a) of this section other than paragraph (8) are met with respect to a plan, the court, on request of the proponent of the plan, shall confirm the plan notwithstanding the requirements of such paragraph if the plan does not discriminate unfairly, and is fair and equitable, with respect to each class of claims or interests that is impaired under, and has not accepted, the plan.
(2)For the purpose of this subsection, the condition that a plan be fair and equitable with respect to a class includes the following requirements:
(B)With respect to a class of unsecured claims—
(i)the plan provides that each holder of a claim of such class receive or retain on account of such claim property of a value, as of the effective date of the plan, equal to the allowed amount of such claim;
https://www.law.cornell.edu/uscode/text/11/1129
This doesn't sound to me like the Liquidating Trustee should have sole discretion to determine a distribution to existing equity account holders.
"Dubovsky may also integrate some of the other 25 M&A candidates Sanofi is looking at."
I wonder if ArriVent is in this basket of 25 M&A candidates that Sanofi is considering. I wonder, also, if Humanigen has already started the integration of lenz into ArriVent's drug development. Our former Board Member, John Hohneker, has significant experience in this regard, including 14 years of experience with Novartis, where he was, "...Senior Vice President and Global Head of Development, Immunology and Dermatology. During his tenure at Novartis, he played a key role in the development, approval and commercialization of several products."
https://ir.arrivent.com/news-releases/news-release-details/arrivent-appoints-john-hohneker-md-its-board-directors
Given Hohneker's familiarity with lenz, his significant experience of Senior Level drug development with Novartis, the product compatibility between the Sanofi and ArriVent pipeline products/indications, and Sanofi's stated "Play to Win" expansion objectives, I think we could see aggressive development of lenz in an ever-increasing array of applications.
https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-13-05-00-00-2880074
Rude, and stupid at the same time.
I understand that many of you, myself included have a tendency to disagree with the theories Jay may have about the future of Humanigen as a company. With that said, that does not make it reasonable for name calling or obnoxious posts like this one.
Jay may read the content and see one thing, while I read the content and see another. We then post our individual thoughts and discuss them without negativity. This is the basis of how humans communicate.
All it takes is a slight amount of compassion to not be a complete dick without cause.
I believe that if anyone is still short, they have been doubly screwed for some time. Paying interest on a near dead illiquid stock would not be a win for them.
I'm unsure how many shares Durrant owns as there is not much edgar filing data for him. For any random searches the standard number that comes up for him is around 70k shares. If Dale owns 10-11mil, and Durrant owns on the super high end of the searchable estimate at something like 1million, I don't see Humanigen owning 90% of their issued shares. We know from the balance sheet the company itself actually owns 0.
The Asset Purchase Agreement was amended to increase the number of Milestone Events, as well as to increase the payments for each Milestone.
The Milestone Events are based on regulatory approvals, of some sort, and revenue levels.
When those Milestone triggers are tripped, as the court obviously deems is a reasonable consideration, all it would take is some type of merger news with Taran, to force a short squeeze. Why wouldn't management want that, if Humanigen controls about 90% of all the shares they issued? Taran could just as easily merge into Humanigen.
The Liquidating Trustee does not need sole discretion to declare a Distribution, based on the Court's determination that Milestone Events will likely be met. In fact, in that case, the Liquidating Trustee is not needed at all. I think this is a last ditch attempt to save the financial asses of the brokerages that are short HGEN, before we rejoin the share structure, with the IP.
Just so I understand, are you implying they have intentionally not met section 1129(b) so they would be forced or have reason to modify the combined plan?
If that were the case, and it was not already met the judge would not have approved the combined plan. The only method forward utilizing that idea is for the liquidating trustee is to come forward and say the approved combined plan was a farce. I'm not sure that's a feasible option or a method which we would or could receive anything.
i guess you dont remember the last bankruptcy. shareholders were included in the restructuring
I don't agree that shareholders are shut out. I don't think management would be reserving the right to further, "...modify the Combined Plan and Disclosure Statement to the extent, if any, that Confirmation pursuant to section 1129(b) of the Bankruptcy Code requires any such modification."
No, I've never spoken to Durrant. My only contact was when he replied to a compassionate use query from me, on behalf of someone else.
The latest docketed item, filed today, contains redactions. This is at least the third time information has been sealed or redacted. Multiple parties, other than management, may have an interest in withholding information for now.
But the question is, when will we have positive news, whether regulatory or partnership related?
That news will open the floodgate of buying interest, and I think it will disqualify us from continued effort in the bankruptcy court.
By the way, a new US survey finds that 43% of American adults have little or no trust for the medical and pharmaceutical industries.
which was the master plan all along. average people NEVER would have been allowed to buy 14 mm shares well below par value .
its over jay and it was planned to be over .
ill be happy to be proven wrong .
durrant cares so much about shareholders he has not answered a single email to multiple investors.
have you ever even spoken to this guy?
the reason i say what i say is that the last time they went bankrupt shareholders were always part of the new deal. in this one we are specifically shut out .
It's really not that hard to figure out. The key is the amended Asset Purchase Agreement (APA).
That unleashing of additional Milestone Events, and increased payments from reaching those Milestone Events, would satisfy all financial obligations to all classes of creditors, and lead to a Distribution to the existing equity holders.
Once again, "The Debtor intends to request
confirmation under section 1129(b) of the Bankruptcy Code with respect to any Class that has not
accepted or is deemed not to have accepted the Combined Plan and Disclosure Statement pursuant
to the terms of the Combined Plan and Disclosure Statement or section 1129 of the Bankruptcy
Code. The Debtor reserves the right to modify the Combined Plan and Disclosure Statement to
the extent, if any, that Confirmation pursuant to section 1129(b) of the Bankruptcy Code requires
any such modification."
I just never felt assured that this unknown Liquidating Trustee would act in our best interest with sole discretion to determine our Distribution rights. I think there are several financial firms, and the SEC, and the hybrid NIAID/NIH with their financial stake in Moderna's success, that could compromise the decision of the Liquidating Trustee. This may be an initial challenge for the judge's consideration of Section 1129 compliance. But there is plenty of data reflecting how much of Moderna's operating expenses are paid by NIAID and the NIH, and scientists from those agencies are receiving royalties from the sell of this drug, and just today I posted a link to the peer-reviewed British Medical Journal's publication, reflecting that Pfizer failed to disclose that their vaccine resulted in a 36% increase in Serious Adverse Events from the vaccine, compared to the placebo group.
There is no way that Creditors could be paid in full, without a Distribution being declared to existing equity holders. After all, if all the creditors are paid in full, then the company should not be in bankruptcy court.
Followers
|
327
|
Posters
|
|
Posts (Today)
|
14
|
Posts (Total)
|
42851
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |